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It is becoming increasingly recognized that cerebrovascular disease is a contributing factor in the 
pathogenesis of Alzheimer’s disease (AD). A unique 4D-Flow magnetic resonance imaging (MRI) 
technique, phase contrast vastly undersampled isotropic projection imaging, (PC VIPR), enables 
examination of angiographic and quantitative metrics of blood flow in the arteries of the Circle of 
Willis within a single MRI acquisition. Thirty-eight participants with Mild Cognitive Impairment 
(MCI) underwent a comprehensive neuroimaging protocol (including 4D-Flow imaging) and a 
standard neuropsychological battery. A subset of participants (N=22) also underwent lumbar 
puncture and had cerebrospinal fluid (CSF) assayed for AD biomarkers. Cut-offs for biomarker 
positivity in CSF resulting from a Receiver Operating Characteristic (ROC) curve analysis of AD 
cases and controls from the larger Wisconsin Alzheimer’s Disease Research Center cohort were 
used to classify MCI participants as biomarker positive or negative on amyloid-β (Aβ42), total-tau 
and total-tau/Aβ42 ratio. Internal carotid artery (ICA) and middle cerebral artery (MCA) mean 
flow were associated with executive functioning performance, with lower mean flow 
corresponding to worse performance. MCI participants who were biomarker positive for Aβ42 had 
lower ICA mean flow than did those who were Aβ42 negative. In sum, mean ICA and MCA 
arterial flow was associated with cognitive performance in participants with MCI and lower flow 
in the ICA was associated with amyloid positivity. This provides further evidence for vascular 
health as a contributing factor in the etiopathogenesis of AD, and could represent a point to 
intervene in the disease process.
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1. Introduction
Mild Cognitive Impairment (MCI) is defined as cognitive decline below age, sex and 
education adjusted population norms on neuropsychological tests that does not disrupt 
independent functioning in daily life [1, 2]. As MCI can result in variable clinical outcomes 
including dementia due to Alzheimer’s disease (AD), it is important to identify markers that 
might predict these outcomes, such as deposition of extracellular aggregates of amyloid-β 
(Aβ) [3–5]. An amyloid positron emission tomography (PET) study using Pittsburgh 
Imaging Compound B (PiB) as a measure of amyloid deposition found that amongst 65 
individuals with MCI, 69% presented with high PiB binding (cortical standard uptake value 
ratio (SUVR) > 1.5); of these, 67% progressed to dementia due to AD over the following 1–
2 years [6]. Interestingly, only 5% of MCI patients with low amyloid burden progressed to 
dementia due to probable AD during the same study period [6]. However, as the presence or 
absence of amyloid binding does not perfectly predict conversion to AD, it is important to 
examine contributions of other health and pathological markers.
The role of vascular health in the pathogenesis of MCI and AD is increasingly being 
understood as an important contributing factor. The presence of periventricular white matter 
hyperintensities of presumed vascular origin among 698 participants that were either 
cognitively normal or diagnosed with MCI was associated with high amyloid in the brain (as 
measured by florbetapir-PET) and low cerebrospinal fluid (CSF) concentration of the 42 
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amino acid (aggregation-prone isoform of amyloid-β (Aβ42) that correlates inversely with 
plaque load in the brain). Interestingly, this relationship persisted when age, APOE 
genotype, and vascular risk factors were controlled for in their analyses [7]. Given that the 
link between periventricular white matter hyperintensities and amyloid accumulation 
persisted even when accounting for standard vascular risk factors [7], a possible explanation 
is that the mechanics and health of the intracranial vasculature play a role.
Our group has been focusing on intracranial arterial health in particular, using a 4D flow 
magnetic resonance imaging (MRI) technique that allows for imaging of large and medium 
sized cerebral vessels in the Circle of Willis with high spatiotemporal resolution in clinically 
feasible scan times [8–10]. We employ a specific technique termed phase contrast vastly 
undersampled isotropic projection imaging, or PC VIPR. Compared to conventional MRI 
methods for examining flow, such as traditional 3D phase contrast imaging, PC VIPR 
increases the product of volume coverage and spatial resolution by a factor of 30 without 
increasing scan times, as it does not require time consuming phase encoding [10]. 
Furthermore, the technique facilitates measurements of flow, pulsatility, and vessel area that 
can be determined retrospectively. Using this technique, we have previously shown 
decreased mean blood flow and increased pulsatility (a metric of vessel stiffness) in the 
intracranial arteries, from cognitively healthy middle-aged individuals, to cognitively healthy 
older adults and lastly to clinically diagnosed MCI and AD patients [11]. Rivera-Rivera and 
colleagues extended this to examine the properties of the venous system, particularly flow 
and pulsatility, in the superior sagittal sinus, straight sinus, and transverse sinus. In 
participants with AD, transit time of peak flow from the arterial system (middle cerebral 
artery) to the venous system (superior sagittal sinus) was significantly shorter than that in 
age-matched controls, which may be a contributing factor in the impaired clearance of toxic 
metabolites [12]. Furthermore, decreased blood flow in the internal carotid artery (ICA) was 
associated with reduced levels of Aβ42 in the CSF in a mixed sample of cognitively healthy 
and impaired adults [13]; reduced Aβ42 in the CSF is a pathological biomarker profile 
associated with amyloidosis [14] and AD [15]. Decreased blood flow and increased 
pulsatility were also associated with a greater degree of brain atrophy in this same sample 
[13].
In addition to research using the 4D-Flow technique, other recent work has also suggested 
that vessel health may be related to the brain’s capacity to clear metabolites from the 
interstitial space. Toxic metabolites may travel directly from the interstitium to the CSF, or 
from the interstitial space into the perivascular space [16]. Aβ is believed to enter the 
basement membranes of capillaries and arteries that surround smooth muscle cells, move 
along these capillaries and arteries until it reaches the leptomeningeal arteries, and from 
there, is subsequently drained into cervical lymph nodes for clearance [16, 17]. Arterial 
pulsation specifically has been shown to promote exchange of perivascular CSF with 
interstitial fluid [18]. Furthermore, cerebral amyloid angiopathy, whereby amyloid deposits 
along blood vessel walls, is proposed to be a reflection of impaired Aβ clearance [19, 20].
We previously examined 4D flow metrics of blood vessel health in individuals throughout 
the entire AD spectrum; we chose to focus the current study on MCI because it is a stage 
with highly disparate outcomes, ranging from reversion to normal cognition to development 
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of clinical dementia syndromes. Given that many of our most significant results have been 
found when examining the ICA and MCA in our previous studies, we chose to focus on 
these intracranial arteries for the present analyses. We identified participants from the 
Wisconsin Alzheimer’s Disease Research Center (WADRC) with a research diagnosis of 
MCI and 4D flow imaging, with a subset also having CSF biomarker data. We hypothesized 
that amongst MCI patients, those with greater blood flow would have more preserved 
cognitive faculties, as measured via performance on neuropsychological tests. Furthermore, 
we hypothesized that blood flow to the brain would be diminished in individuals with MCI 
with positive biomarkers of CSF Aβ or tau compared to MCI participants who were 
biomarker negative.
2. Methods
2.1. Study Population
Participants were selected from a large cohort, the WADRC, consisting of approximately 
700 individuals spanning the AD spectrum: middle-aged participants both with and without 
a family history of AD, cognitively healthy older control participants, and subjects with 
clinically diagnosed MCI and AD [11, 13]. Participants with MCI are recruited primarily 
from local clinics (or control subjects in longitudinal studies that have shown cognitive 
decline) and diagnosis is confirmed by clinical consensus conference based on established 
clinical criteria [1, 21]. Participants in this study were diagnosed with MCI due to probable 
or possible AD. In addition to having an MCI diagnosis, inclusion criteria included having 
undergone a PC VIPR scan that allowed for measurement of both the left and right internal 
carotid arteries (measured in the distal petrous segment), resulting in a sample of 38 
participants for the present study. All but two (5.3%) of the participants entered the study 
with an MCI diagnosis from a local clinic, with the other two subjects receiving a diagnosis 
of MCI after neuropsychological testing done as part of the WADRC clinical core study. 
One subject entered the study with a presumed diagnosis of dementia due to AD and was 
changed to MCI at consensus conference, whereas the other subject entered as cognitively 
healthy and changed to a diagnosis of MCI at consensus conference. A subset of N=22 
participants underwent a lumbar puncture (LP), which is an optional study procedure. All 
procedures were approved by the University of Wisconsin School of Medicine and Public 
Health Institutional Review Board, in accordance with the Helsinki Declaration of 1975.
2.2. MR Imaging Protocol
Subjects were scanned using an 8-channel head coil (Excite HD Brain Coil, GE Healthcare) 
on a clinical 3T MRI system (MR750, GE Healthcare, Waukesha, WI). The PC VIPR 
method was used to acquire four dimensional flow data [10]. Scan parameters for the PC 
VIPR acquisition were as detailed: venc = 80 cm/s, imaging volume = (22 cm)3, acquired 
isotropic spatial resolution = (0.7 mm)3, TR/TE=7.4/2.7ms, flip angle α=10°, bandwidth = 
83.3KHz, 14,000 projection angles, scan time ~ 7 min, retrospective cardiac gating 
reconstructed into 20 cardiac phases with temporal interpolation [22].
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2.3. Flow Analysis
Velocity vector fields were extracted from the PC VIPR data sets and used for hemodynamic 
evaluation. Matlab (The Mathworks, Natick, MA) was used for segmentation of the arterial 
tree from PC angiograms generated from the 4D-Flow MRI data. Interactive flow 
visualization and selection of planes for quantitative analysis were conducted in EnSight 
(CEI, Apex, NC); flow analysis planes were manually placed orthogonal to the vessel 
orientation in the distal petrous ICA and the middle of the M1 segment of the MCA. Using a 
customized Matlab tool, 2D-cine image series with through-plane velocities were generated 
from 4D-Flow MRI data at the selected planes of interest [23]. Measurements were taken 
from both the left and right ICA and the left and right MCA, and these values were averaged 
to obtain mean ICA and MCA flow metrics, respectively [13, 24]. In three participants the 
MCA was not able to be segmented successfully, so those participants were excluded from 
the MCA analyses only.
2.4. Neuropsychological Testing
Longitudinal cognitive data is collected annually for cognitively healthy older adult (>65y), 
MCI and dementia participants in the WADRC Clinical Core cohort. At each visit, 
participants complete a comprehensive neuropsychological test battery examining a number 
of different cognitive domains; in the study herein, we examined tests of episodic memory 
(Rey Auditory Verbal Learning Test (RAVLT) total trials 1–5 and delayed recall, and 
Wechsler Memory Scale – Revised - Logical Memory Immediate and Delayed recall) and 
executive function (Trail Making Test B (TMT-B), Wechsler Adult Intelligence Scale-
Revised Digit Symbol (WAIS-DS) and animal naming (category fluency)). 
Neuropsychological data from the study visit closest to the MRI was included in analyses 
(mean interval 53.68 days; SD: 41.83). In order to reduce the number of comparisons and 
the likelihood of Type 1 error, we created composite Z scores for executive function (TMT-
B, WAIS-DS and Animal Naming; TMT-B was first reverse-scored so that higher scores 
indicated better performance) and memory (RAVLT and logical memory immediate and 
delay). One subject did not complete the RAVLT or logical memory measures at the 
neuropsychological visit closest to the MRI scan date, so was excluded from the memory 
composite analyses only.
2.5. CSF Collection and Analysis
LP for CSF collection was conducted in the morning following at least a 12 hour fast. The 
LP procedure was performed as follows: a Sprotte spinal needle was inserted into the L3-L4 
or L4-L5 vertebral interspace, with slow suction used to withdraw CSF. Within 30 minutes 
of collection, centrifugation of the CSF to remove red blood cells or other debris was 
performed. The CSF was then aliquoted into 0.5ml polypropylene tubes and stored at −80˚C 
[25] until being sent in bulk for analysis at the Clinical Neurochemistry Lab at the 
Sahlgrenska Academy of the University of Gothenburg, Sweden. The CSF samples were 
assayed for total-tau and amyloid beta 1–42 (Aβ42) using commercially available enzyme-
linked immunosorbent assay (ELISA) methods (INNOTEST assays, Fujiurebio, Ghent 
Belgium) as described previously [26–28]. Board-certified laboratory technicians blinded to 
clinical diagnosis performed all analyses on one occasion per batch sent, with two batches 
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sent. 17 of the participants had CSF analyzed in batch 1, and 5 in batch 2; a statistician (DN) 
created a conversion factor to account for inter-batch variability (Norton et al., in 
preparation). All samples were analyzed according to protocols approved by the Swedish 
Board of Accreditation and Conformity Assessment (SWEDAC) using either of two batches 
of reagents (intra-assay coefficient of variation <10%).
2.6. Statistical Analysis
Multiple linear regression analyses were conducted in SPSS Version 22. Models included 
either bilateral mean blood flow in the ICA or MCA or the difference in flow between the 
left and right ICA or left and right MCA (components used to generate the mean flow 
variable) as the predictor variable, memory or executive function composite scores as the 
outcome variable, with age at MRI scan, sex, years of education, and interval between MRI 
scan and cognitive test date as covariates. The absolute value of the difference between left 
and right flow was examined to test whether it was an overall impairment in blood flow to 
the brain, or a more localized/lateral arterial issue affecting cognitive performance.
Receiver operating characteristic (ROC) curves were used to develop cut-offs of biomarker 
positivity in a separate sample of 38 participants with dementia due to AD and 40 
cognitively healthy adults described in more detail elsewhere (Clark et al., unpublished 
data). For total tau and total-tau/Aβ42, values at and above the value that maximizes 
Youden’s J (Youden’s J = sensitivity + specificity - 1) were defined as biomarker positive. 
Given the inverse relationship between Aβ42 in CSF and Aβ oligomers and plaques in the 
brain, values at or below the cut-off for Aβ42 were defined as biomarker positive. The 
cutoffs used were as follows: Aβ42 (6.156 natural log scale, 471.54 ng/L), total tau (461.26 
ng/L) and total-tau to Aβ42 ratio (total-tau/Aβ42) (0.62).
To compare demographic and clinical features between biomarker positive and negative 
groups, nonparametric tests were used due to small group sizes. Mann Whitney U Tests and 
Fisher’s Exact Tests were used for continuous data and categorical data, respectively. Of 
particular interest to the study were the Mann Whitney U tests performed to examine if ICA 
and MCA flow differed based on positivity or negativity for the following biomarkers: Aβ42, 
total-tau or total-tau/Aβ42 ratio. Post hoc multiple linear regression models for significant 
biomarker positivity results were run adding standard covariates from the literature; age, sex, 
and APOE ε4 carrier status (with biomarker positivity status as the predictor of interest and 
flow as the outcome). The reason for running both Mann Whitney U tests followed by linear 
regression models with covariates was to balance possible over-modeling in this small 
sample size with the desire to include covariates that are standard in the literature; if the 
general conclusions hold up in both models (one more basic that is more appropriate for the 
small sample size, while another that incorporates standard covariates), then this provides 
further confidence in our findings. Although biomarker cut-offs can simplify interpretation 
and improve clinical applicability, they ignore the potentially important underlying 
continuous distribution of the biomarker, especially for individuals whose biomarker levels 
are very close to the cut-off. Therefore, for associations where the Mann Whitney U test was 
significant, we also performed post-hoc multiple linear regression models with continuous 
CSF biomarker data (in place of the binary factor of biomarker positivity or negativity), with 
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the same covariates as the model above, to determine whether biomarkers on a continuous 
scale predicted blood flow. Furthermore, multiple linear regression models were checked to 
prevent against significant violations of the normality (via Kolmogorov-Smirnov tests) or 
homoscedasticity assumptions. Statistical significance was set at p <.05, and trends were 
reported when p < .1.
3. Results
Demographic and clinical information for the N=38 participants with MCI is detailed in 
Table 1.
3.1. ICA and MCA Mean Flow and Cognition
Higher flow in the ICA measured using PC VIPR was found to be associated with a higher 
executive composite Z score, with an unstandardized B estimate of .466 (SE: .109), (t[DF32] 
= 4.283, p < .001) (Figure 1A). This relationship persisted when removing the two possible 
outliers with the lowest adjusted executive functioning performance and the two possible 
outliers with the highest mean flow values; the participants removed in this sensitivity 
analysis, however, were all within three standard deviations of the mean value. Compared to 
the base model with just covariates (age, sex, years of education and interval between MRI 
and cognitive testing) for which R2 = .150, the R2 change when ICA mean flow was added 
to the model was 0.310. In contrast, ICA flow was not predictive of memory performance 
(unstandardized B = .203 (SE: .131); p = .130) and the difference between right and left ICA 
flow was neither predictive of executive function (unstandardized B = .290 (SE: .255);. p = .
263) nor memory (unstandardized B = .087 (SE: .256); p = .738).
A similar pattern of results was seen for the subjects in regards to MCA flow. Higher flow 
was associated with greater executive function, with an unstandardized B estimate of .927 
(SE: .223), (t[DF29] = 4.147, p < .001) (Figure 1B). The base model with only covariates 
had an R2 of 0.201, and adding MCA flow into the model resulted in an R2 change of 0.298. 
As above, there were no significant relationships between MCA flow and memory 
performance (unstandardized B = .153 (SE: .296); p =.610) and the difference between right 
and left MCA flow was neither predictive of executive function (unstandardized B = .234 
(SE: .519); p = .655) or memory (unstandardized B = .791 (SE: .533); p = .149).
3.3. Biomarker Positivity and Mean Flow
Half (N=11 out of 22, 50%) of MCI participants with assayed CSF were Aβ42 positive, 
59.1% (N=13 out of 22) were total-tau positive and 63.6% (N=14 out of 22) were total-tau/
Aβ42 positive. In regards to demographic and clinical characteristics, participants who were 
total-tau positive had lower MMSE scores (p =.011), and had a trend towards a lower 
prevalence of diabetes (p=.055) compared to the tau negative group; there was a trend 
towards increasing prevalence of ε4 carriage in the amyloid positive group (p = .08) 
compared to the amyloid negative group. In the total-tau/Aβ42 positive group, there was a 
trend towards increased age (p=.082) and decreased MMSE scores (p=.059). All other 
demographic and clinical variables did not differ between groups, including executive and 
memory composite scores. Compared to Aβ42 negative participants, MCI participants with 
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Aβ42 positivity had lower mean flow in the ICA (U = 28, p = .034; mean rank Aβ42-negative 
14.45, mean rank Aβ42-positive 8.55) (Figure 2). This difference persisted while controlling 
for standard covariates (in a multiple linear regression model) of age, sex and APOE ε4, 
with an unstandardized B estimate of −1.111 (SE: .424) (t[DF17] = −2.619, p = .018) for 
amyloid biomarker positivity status on ICA mean flow. In a model examining Aβ42 levels as 
a continuous variable, lower levels of Aβ42 were associated with lower ICA flow at a trend 
level, with an unstandardized B of 1.029 (SE: .516) (t[DF17] = 1.994, p = .062). In contrast, 
MCA mean flow was not associated with amyloid biomarker positivity on the Mann 
Whitney test (p = .314). Flow in the ICA and MCA both did not differ based on total-tau or 
total-tau/Aβ42 biomarker positivity.
4. Discussion
In this study examining intracranial arterial health metrics of the ICA and MCA in 
participants with MCI, we found that lower flow correlated with worse performance on 
neuropsychological tests of executive function, and that participants with lower mean flow in 
the ICA were more likely to be amyloid positive. No relationships were observed in this 
sample between flow and performance on a composite memory metric, nor with tau or tau/
Aβ42 ratio positivity. Lastly, laterality of blood flow did not predict any of the outcomes 
examined.
Prior studies have demonstrated associations between reduced cerebral perfusion measured 
via arterial spin labeling (ASL) and cognitive decline in MCI. For example, a study of 48 
older adults with MCI (mean age 76.3y at baseline) found that decreased cerebral perfusion 
predicted cognitive decline over an average of 2.7 years on the Clinical Dementia Rating 
(CDR) Scale Sum of Boxes, Stroop Switching, and California Verbal Learning Test [29]. 
Although cross-sectional, our results also support that reduced cerebral blood flow even 
within the larger arterial vessels (e.g., ICA and MCA mean flow) is associated with lower 
cognitive performance. Evidence suggests vascular disease often negatively impacts 
cognitive performance specifically in the executive functioning domain [30, 31]. In a study 
of 130 individuals with hypertension, increased small vessel disease was associated with 
poorer executive functioning performance, but not with memory performance [32], a similar 
pattern to what we observed in our study. Additionally, in a separate sample (n=94) of 
cognitively healthy older adults, subcortical ischemic vascular disease significantly predicted 
worse performance on executive functioning metrics, but not memory measures [33].
Reduced cortical perfusion has also been associated with elevated amyloid burden in 
addition to cognitive impairment. Analysis of 182 participants (cognitively normal, early and 
late MCI, and AD) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) found 
that an increased amount of amyloid (as measured via florbetapir-PET) was associated with 
reduced perfusion in the entorhinal, inferior temporal, inferior parietal, and precuneus 
cortices [34]. Furthermore, a study of 27 cognitively normal older adults and 16 adults with 
amnestic MCI found a trend towards lower cerebral blood flow in adults with positive 
neuroimaging markers for amyloid compared to adults negative for amyloid markers [35]. 
What differentiates the present research from prior studies is that we are examining 
macroscopic blood flow in large intracranial arteries, as opposed to local cerebral tissue 
Berman et al. Page 8
J Alzheimers Dis. Author manuscript; available in PMC 2018 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
perfusion measured via ASL. Although our prior studies suggest a positive correlation 
between measurements of blood flow in the large arteries and cortical perfusion [36], there is 
utility in using both methods in the study of the etiopathogenesis of AD as they assess 
different aspects of cerebrovascular health.
Our finding that lower mean ICA and MCA blood flow are associated with greater cognitive 
impairment and that lower flow in the ICA is associated with amyloid positivity provides 
further evidence for a relationship between vascular health and AD pathogenesis. A recent 
review stressed the importance of research on vascular health in cognitively impaired 
populations and proposed that vascular metrics may help to explain heterogeneous 
biomarker profiles [37]. While effects on amyloid clearance may be one mechanism, 
vascular dysfunction may also affect cognitive decline through a non-clearance dependent 
mechanism. For instance, differences in vascular health could partially explain the oft-cited 
observation that cognitively healthy individuals can be amyloid positive yet not display 
clinical symptoms of dementia due to AD [38–40]. Perhaps a more optimal vascular health 
status protects these individuals with AD pathology from manifesting the disease clinically, 
though this is speculative and requires further research. Interestingly, in our study, MCI 
participants who were biomarker positive for amyloid had lower ICA blood flow than did 
those who were amyloid negative, further suggesting a link between vascular pathology and 
amyloid pathology. Perhaps the reason only amyloid, rather than tau, showed a relationship 
with ICA flow is that amyloid is particularly toxic to the vasculature [17] or because Aβ 
abnormalities are more pronounced in CSF earlier in the AD trajectory while tau 
abnormalities accumulate in the CSF as the disease progresses [41]. A possible explanation 
for why ICA flow was significantly associated with amyloid positivity and MCA flow was 
not is that given the small sample size, there is a larger probability for type II error, but this 
merits further study in a larger group of participants with MCI.
Our study has limitations that should be mentioned. Data was not collected for potentially 
confounding factors that may affect cerebral hemodynamics, such as sleep apnea, ejection 
fraction or RR interval. The sample size of participants with MCI who have PC VIPR data is 
small, and this is reduced further when examining 4D blood flow in concert with CSF 
biomarkers; future studies plan to conduct analyses in larger sample sizes to confirm the 
present results. Due to this small sample size, there is a higher likelihood of type II error, 
which may explain why no relationships were seen with blood flow and memory 
performance nor with amyloid positivity and MCA mean flow. Furthermore, although CSF 
biomarker values are not dichotomous by nature, we chose to examine cut-offs for 
biomarker positivity because we wanted to stratify the patients using a more clinically 
interpretable variable; however, we also examined significant results post-hoc as continuous 
variables and observed a trend level relationship for amyloid. Although a linear trend of time 
was accounted for in some statistical models, having a more condensed time frame of the 
MRI, LP and neuropsychological visits could lend greater strength to the conclusions, 
however, despite the elapses in time, we were able to detect relationships in this small 
sample. In regards to cognition, analyses presented herein are cross-sectional in nature, and 
efforts are underway to examine the role of 4D blood flow metrics on longitudinal cognitive 
performance and conversion from MCI to AD. Furthermore, we plan to incorporate 
pulsatility index, a surrogate metric of vessel stiffness, into future analyses, as an additional 
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metric of vessel health and also examine the relationship between arterial health metrics and 
performance on visuospatial cognitive tests. Overall, this study examines blood flow in the 
ICA and MCA using a unique methodology, four-dimensional flow MRI, and relates it to 
established biomarker and cognitive phenotypes associated with AD pathology. The results 
provide additional evidence of the interrelationship between vascular factors and AD that 
could have important implications for research and clinical care of patients with MCI.
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Figure 1. Greater mean flow in the ICA and MCA correlates with better executive functioning 
performance
(A) ICA mean flow in participants with MCI is on the x-axis, and executive function 
composite score adjusted for covariates (age, gender, interval between MRI and 
neuropsychological testing, and years of education) is on the y-axis. A higher composite Z-
score indicates better performance (N=38, p<.001); (B) MCA mean flow in participants with 
MCI is on the x-axis and executive function composite score adjusted for covariates (age, 
gender, interval between MRI and neuropsychological testing, and years of education) is on 
the y-axis (N=35, p<.001).
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Figure 2. Amyloid positivity is associated with reduced blood flow in the ICA
MCI participants who were amyloid positive (Aβ42 ≤ 471.54 ng/L) had reduced mean blood 
flow measured in the distal petrous portion of the ICA. Biomarker positivity is plotted on the 
x-axis and unadjusted ICA mean flow data is on the y-axis (N=22, p = 0.034).
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Table 1
Demographic and Clinical Characteristics of Participants with MCI
Characteristic
N 38
Age (mean; SD) 73.25; 8.42
Sex (N; % Female) 16, 42.1%
Education (years; mean; SD) 15.66; 2.65
Parental history of dementia (N; % positive) 18; 47.4%
APOE ε4 positive (N; %) 20; 52.6%
Mini-Mental State Exam (mean; SD) 26.18; 2.46
CDR Global (median; range) 0.5; 0–1
CDR Sum of Boxes (mean; SD) 1.855; 1.25
Mean flow in the ICA, ml/sec (mean; SD) 3.70; 0.90
Mean flow in the MCA, ml/sec (mean; SD) 1.97; .46
Flow difference (abs value) between left and right ICA, ml/sec (mean; SD) 0.64; 0.49
Flow difference (abs value) between left and right MCA, ml/sec (mean; SD) 0.27; 0.25
Diagnosed with Diabetes (N; %) 6; 15.8%
Systolic Blood Pressure, mmHg (mean; SD) 132.53; 18.53
Diastolic Blood Pressure, mmHg (mean; SD) 73.61; 8.91
Total Cholesterol (mean; SD) 192.32; 49.97
HDL Cholesterol (mean; SD) 58.92; 17.52
Taking BP lowering medication (N; %) 23; 60.5%
Interval between MRI and neuropsychological testing, days (mean; SD; range) 53.68; 41.83; −74 to 143 days
Interval between MRI and LP, days (mean; SD; range) −32.77; 124.87; −574 to 0 days
MCI Subtype N=27 single domain amnestic MCI
N=10 multi-domain amnestic MCI (n=6 memory + executive 
function; n=1 memory+ executive function + visuospatial; 
n=1 memory + executive function + language; n=2 memory + 
language)
N=1 non-amnestic MCI (executive function)
J Alzheimers Dis. Author manuscript; available in PMC 2018 January 01.
